Vaultree Achieves Google Cloud Ready - AlloyDB Designation
Vaultree, the Data-In-Use Encryption leader, today announced that it has successfully achieved Google Cloud Ready - AlloyDB designation for AlloyDB for PostgreSQL, Google Cloud’s newest fully managed PostgreSQL-compatible database service for most demanding enterprise database workloads.
This market-expanding milestone follows Vaultree’s successful $12.8 million series A funding round, selection as the only Irish recipient of the European Innovation Council (EIC) grant and the appointment of renowned tech industry veteran Rinki Sethi to its executive board of directors.
Google Cloud Ready - AlloyDB is a new designation for the solutions of Google Cloud’s technology partners that integrate with AlloyDB. These partners have closely collaborated with Google Cloud to add support for AlloyDB into their solutions and tune their existing functionality for optimal outcomes. This designation recognizes the partner solutions that have met a core set of functional requirements and been validated in collaboration with Google Cloud engineering teams.
“Achieving the Google Cloud Ready - AlloyDB designation demonstrates that Vaultree’s data encryption in use capabilities have been validated by Google Cloud to integrate with AlloyDB to provide an excellent experience for customers,” said Ritika Suri, Director, Technology Partnerships at Google Cloud.
By earning this designation, Vaultree has proven its product has met a core set of functional and interoperability requirements when integrating with AlloyDB and refined documentation for ease of onboarding by the companies’ mutual customers. This designation enables customers to discover and have confidence that the Vaultree products they use today work well with AlloyDB and save time evaluating them.
As part of the program, Vaultree enjoys more opportunities to collaborate closely with Google Cloud partner engineering and AlloyDB teams to develop joint roadmaps.
Google Cloud’s ecosystem is designed to support industry-focused digital transformation. With this partnership, Vaultree enables customers to rely on end-to-end solutions through a reliable, fast and seamless integration of the most advanced encryption product on the market to rid themselves of the danger of plaintext data exposure.
“Breaches or leaks will continue to happen, no matter how many tools are in the first line of defense, but the second line of defense – encryption – has been neglected for decades because data still has to be decrypted in order to be worked with,” said Tilo Weigandt, COO and co-founder of Vaultree. “Our goal is to end that with our product and help enterprises to not just be compliant but secure and leave the worries behind.”
Vaultree with Google Cloud’s AlloyDB for PostgreSQL fulfills this goal, allowing customers to choose what to encrypt, and manage their own keys with zero learning and changes to the existing query languages, data structure, architecture, network topology or policies/permissions — all with minimal performance loss in the cloud.
“We are paving the way to a new era of cloud-based data protection by designing and offering the world’s first always-encrypted, Data-In-Use solution with unparalleled performance and simplicity, powered by Vaultree with Google’s AlloyDB for PostgreSQL,” said Ryan Lasmaili, CEO and co-founder of Vaultree. “Partnering with Google Cloud brings us reliability, flexibility and freedom to innovate and engage with a key player in an ever-changing industry to create the best data privacy solutions for enterprises of any kind, driving security and profitability, and accelerating digital transformation.”
To learn more about Vaultree’s expertise with AlloyDB, visit. To learn more about Google Cloud Ready - AlloyDB and its benefits, visit.
About Vaultree
Vaultree has developed the world’s first Fully Functional Data-in-Use Encryption solution that solves the industry’s fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare/pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale, without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree’s Data-In-Use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005299/en/
Contact information
Matt Culbertson
prforvaultree@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom